---
_id: '12131'
abstract:
- lang: eng
text: Replication-incompetent adenoviral vectors have been extensively used as a
platform for vaccine design, with at least four anti-COVID-19 vaccines authorized
to date. These vaccines elicit neutralizing antibody responses directed against
SARS-CoV-2 Spike protein and confer significant level of protection against SARS-CoV-2
infection. Immunization with adenovirus-vectored vaccines is known to be accompanied
by the production of anti-vector antibodies, which may translate into reduced
efficacy of booster or repeated rounds of revaccination. Here, we used blood samples
from patients who received an adenovirus-based Gam-COVID-Vac vaccine to address
the question of whether anti-vector antibodies may influence the magnitude of
SARS-CoV-2-specific humoral response after booster vaccination. We observed that
rAd26-based prime vaccination with Gam-COVID-Vac induced the development of Ad26-neutralizing
antibodies, which persisted in circulation for at least 9 months. Our analysis
further indicates that high pre-boost Ad26 neutralizing antibody titers do not
appear to affect the humoral immunogenicity of the Gam-COVID-Vac boost. The titers
of anti-SARS-CoV-2 RBD IgGs and antibodies, which neutralized both the wild type
and the circulating variants of concern of SARS-CoV-2 such as Delta and Omicron,
were independent of the pre-boost levels of Ad26-neutralizing antibodies. Thus,
our results support the development of repeated immunization schedule with adenovirus-based
COVID-19 vaccines.
acknowledgement: We thank Sergey Kulemzin, Grigory Efimov, Yuri Lebedin, Alexander
Taranin and Rudolf Valenta for providing reagents. Figures were created with the
help of BioRender.com. This work was supported by the Russian Science Foundation
(Project 21-15-00286). Byazrova M.G. was supported by the RUDN University Strategic
Academic Leadership Program.
article_number: '145'
article_processing_charge: No
article_type: original
author:
- first_name: Maria G.
full_name: Byazrova, Maria G.
last_name: Byazrova
- first_name: Ekaterina A.
full_name: Astakhova, Ekaterina A.
last_name: Astakhova
- first_name: Aygul
full_name: Minnegalieva, Aygul
id: 87DF77F0-1D9A-11EA-B6AE-CE443DDC885E
last_name: Minnegalieva
- first_name: Maria M.
full_name: Sukhova, Maria M.
last_name: Sukhova
- first_name: Artem A.
full_name: Mikhailov, Artem A.
last_name: Mikhailov
- first_name: Alexey G.
full_name: Prilipov, Alexey G.
last_name: Prilipov
- first_name: Andrey A.
full_name: Gorchakov, Andrey A.
last_name: Gorchakov
- first_name: Alexander V.
full_name: Filatov, Alexander V.
last_name: Filatov
citation:
ama: Byazrova MG, Astakhova EA, Minnegalieva A, et al. Anti-Ad26 humoral immunity
does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac
booster vaccination. npj Vaccines. 2022;7. doi:10.1038/s41541-022-00566-x
apa: Byazrova, M. G., Astakhova, E. A., Minnegalieva, A., Sukhova, M. M., Mikhailov,
A. A., Prilipov, A. G., … Filatov, A. V. (2022). Anti-Ad26 humoral immunity does
not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac
booster vaccination. Npj Vaccines. Springer Nature. https://doi.org/10.1038/s41541-022-00566-x
chicago: Byazrova, Maria G., Ekaterina A. Astakhova, Aygul Minnegalieva, Maria M.
Sukhova, Artem A. Mikhailov, Alexey G. Prilipov, Andrey A. Gorchakov, and Alexander
V. Filatov. “Anti-Ad26 Humoral Immunity Does Not Compromise SARS-COV-2 Neutralizing
Antibody Responses Following Gam-COVID-Vac Booster Vaccination.” Npj Vaccines.
Springer Nature, 2022. https://doi.org/10.1038/s41541-022-00566-x.
ieee: M. G. Byazrova et al., “Anti-Ad26 humoral immunity does not compromise
SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination,”
npj Vaccines, vol. 7. Springer Nature, 2022.
ista: Byazrova MG, Astakhova EA, Minnegalieva A, Sukhova MM, Mikhailov AA, Prilipov
AG, Gorchakov AA, Filatov AV. 2022. Anti-Ad26 humoral immunity does not compromise
SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination.
npj Vaccines. 7, 145.
mla: Byazrova, Maria G., et al. “Anti-Ad26 Humoral Immunity Does Not Compromise
SARS-COV-2 Neutralizing Antibody Responses Following Gam-COVID-Vac Booster Vaccination.”
Npj Vaccines, vol. 7, 145, Springer Nature, 2022, doi:10.1038/s41541-022-00566-x.
short: M.G. Byazrova, E.A. Astakhova, A. Minnegalieva, M.M. Sukhova, A.A. Mikhailov,
A.G. Prilipov, A.A. Gorchakov, A.V. Filatov, Npj Vaccines 7 (2022).
date_created: 2023-01-12T12:02:54Z
date_published: 2022-11-15T00:00:00Z
date_updated: 2023-08-04T08:52:40Z
day: '15'
ddc:
- '570'
department:
- _id: FyKo
doi: 10.1038/s41541-022-00566-x
external_id:
isi:
- '000884278600004'
pmid:
- '36379998'
file:
- access_level: open_access
checksum: ddaac096381565b2b4b7dcc34cdbc4ee
content_type: application/pdf
creator: dernst
date_created: 2023-01-23T11:22:09Z
date_updated: 2023-01-23T11:22:09Z
file_id: '12347'
file_name: 2022_njpVaccines_Byazrova.pdf
file_size: 1856046
relation: main_file
success: 1
file_date_updated: 2023-01-23T11:22:09Z
has_accepted_license: '1'
intvolume: ' 7'
isi: 1
keyword:
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Immunology
- SARS-COV-2
- COVID
language:
- iso: eng
license: https://creativecommons.org/licenses/by/4.0/
month: '11'
oa: 1
oa_version: Published Version
pmid: 1
publication: npj Vaccines
publication_identifier:
issn:
- 2059-0105
publication_status: published
publisher: Springer Nature
quality_controlled: '1'
scopus_import: '1'
status: public
title: Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody
responses following Gam-COVID-Vac booster vaccination
tmp:
image: /images/cc_by.png
legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
short: CC BY (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 7
year: '2022'
...
---
_id: '12252'
abstract:
- lang: eng
text: The COVID−19 pandemic not only resulted in a global crisis, but also accelerated
vaccine development and antibody discovery. Herein we report a synthetic humanized
VHH library development pipeline for nanomolar-range affinity VHH binders to SARS-CoV-2
variants of concern (VoC) receptor binding domains (RBD) isolation. Trinucleotide-based
randomization of CDRs by Kunkel mutagenesis with the subsequent rolling-cycle
amplification resulted in more than 1011 diverse phage display
library in a manageable for a single person number of electroporation reactions.
We identified a number of nanomolar-range affinity VHH binders to SARS-CoV-2 variants
of concern (VoC) receptor binding domains (RBD) by screening a novel synthetic
humanized antibody library. In order to explore the most robust and fast method
for affinity improvement, we performed affinity maturation by CDR1 and CDR2 shuffling
and avidity engineering by multivalent trimeric VHH fusion protein construction.
As a result, H7-Fc and G12x3-Fc binders were developed with the affinities in
nM and pM range respectively. Importantly, these affinities are weakly influenced
by most of SARS-CoV-2 VoC mutations and they retain moderate binding to BA.4\5.
The plaque reduction neutralization test (PRNT) resulted in IC50 = 100 ng\ml and
9.6 ng\ml for H7-Fc and G12x3-Fc antibodies, respectively, for the emerging Omicron
BA.1 variant. Therefore, these VHH could expand the present landscape of SARS-CoV-2
neutralization binders with the therapeutic potential for present and future SARS-CoV-2
variants.
acknowledgement: The authors declare that this study received funding from Immunofusion.
The funder was not involved in the study design, collection, analysis, interpretation
of data, the writing of this article or the decision to submit it for publication.
article_number: '965446'
article_processing_charge: No
article_type: original
author:
- first_name: Dmitri
full_name: Dormeshkin, Dmitri
last_name: Dormeshkin
- first_name: Michail
full_name: Shapira, Michail
last_name: Shapira
- first_name: Simon
full_name: Dubovik, Simon
last_name: Dubovik
- first_name: Anton
full_name: Kavaleuski, Anton
id: 4968f7ad-eb97-11eb-a6c2-8ed382e8912c
last_name: Kavaleuski
orcid: 0000-0003-2091-526X
- first_name: Mikalai
full_name: Katsin, Mikalai
last_name: Katsin
- first_name: Alexandr
full_name: Migas, Alexandr
last_name: Migas
- first_name: Alexander
full_name: Meleshko, Alexander
last_name: Meleshko
- first_name: Sergei
full_name: Semyonov, Sergei
last_name: Semyonov
citation:
ama: Dormeshkin D, Shapira M, Dubovik S, et al. Isolation of an escape-resistant
SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library. Frontiers
in Immunology. 2022;13. doi:10.3389/fimmu.2022.965446
apa: Dormeshkin, D., Shapira, M., Dubovik, S., Kavaleuski, A., Katsin, M., Migas,
A., … Semyonov, S. (2022). Isolation of an escape-resistant SARS-CoV-2 neutralizing
nanobody from a novel synthetic nanobody library. Frontiers in Immunology.
Frontiers Media. https://doi.org/10.3389/fimmu.2022.965446
chicago: Dormeshkin, Dmitri, Michail Shapira, Simon Dubovik, Anton Kavaleuski, Mikalai
Katsin, Alexandr Migas, Alexander Meleshko, and Sergei Semyonov. “Isolation of
an Escape-Resistant SARS-CoV-2 Neutralizing Nanobody from a Novel Synthetic Nanobody
Library.” Frontiers in Immunology. Frontiers Media, 2022. https://doi.org/10.3389/fimmu.2022.965446.
ieee: D. Dormeshkin et al., “Isolation of an escape-resistant SARS-CoV-2
neutralizing nanobody from a novel synthetic nanobody library,” Frontiers in
Immunology, vol. 13. Frontiers Media, 2022.
ista: Dormeshkin D, Shapira M, Dubovik S, Kavaleuski A, Katsin M, Migas A, Meleshko
A, Semyonov S. 2022. Isolation of an escape-resistant SARS-CoV-2 neutralizing
nanobody from a novel synthetic nanobody library. Frontiers in Immunology. 13,
965446.
mla: Dormeshkin, Dmitri, et al. “Isolation of an Escape-Resistant SARS-CoV-2 Neutralizing
Nanobody from a Novel Synthetic Nanobody Library.” Frontiers in Immunology,
vol. 13, 965446, Frontiers Media, 2022, doi:10.3389/fimmu.2022.965446.
short: D. Dormeshkin, M. Shapira, S. Dubovik, A. Kavaleuski, M. Katsin, A. Migas,
A. Meleshko, S. Semyonov, Frontiers in Immunology 13 (2022).
date_created: 2023-01-16T09:56:57Z
date_published: 2022-09-16T00:00:00Z
date_updated: 2023-08-04T09:49:24Z
day: '16'
ddc:
- '570'
department:
- _id: LeSa
doi: 10.3389/fimmu.2022.965446
external_id:
isi:
- '000862479100001'
file:
- access_level: open_access
checksum: f8f5d8110710033d0532e7e08bf9dad4
content_type: application/pdf
creator: dernst
date_created: 2023-01-30T09:22:26Z
date_updated: 2023-01-30T09:22:26Z
file_id: '12443'
file_name: 2022_FrontiersImmunology_Dormeshkin.pdf
file_size: 5695892
relation: main_file
success: 1
file_date_updated: 2023-01-30T09:22:26Z
has_accepted_license: '1'
intvolume: ' 13'
isi: 1
keyword:
- Immunology
- Immunology and Allergy
- COVID-19
- SARS-CoV-2
- synthetic library
- RBD
- neutralization nanobody
- VHH
language:
- iso: eng
month: '09'
oa: 1
oa_version: Published Version
publication: Frontiers in Immunology
publication_identifier:
issn:
- 1664-3224
publication_status: published
publisher: Frontiers Media
quality_controlled: '1'
scopus_import: '1'
status: public
title: Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel
synthetic nanobody library
tmp:
image: /images/cc_by.png
legal_code_url: https://creativecommons.org/licenses/by/4.0/legalcode
name: Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
short: CC BY (4.0)
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 13
year: '2022'
...